Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$18.70
+0.10 (+0.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $13.4M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$553M
P/E
17.0x
↓EV/EBITDA
6.0x
↓ROE
7.1%
↑Gross Margin
47.6%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.3%
FCF CAGR
—
FCF margin
32.0%
FCF / Net income
2.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $222.7M · net income $32.3M · FCF $71.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $222.7M | $222.7M | $201.7M | $191.8M | $190.6M |
| Net Income | $32.3M | $32.3M | $1.0M | $-11.6M | $500000.00 |
| EBITDA | $65.5M | $65.5M | $27.7M | $12.1M | $24.3M |
| EPS | — | — | 0.03 | -0.38 | 0.02 |
| Gross Margin | 47.6% | 47.6% | 39.2% | 40.5% | 42.2% |
| Operating Margin | 17.0% | 17.0% | -1.9% | -10.1% | -0.1% |
| Net Margin | 14.5% | 14.5% | 0.5% | -6.0% | 0.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.20 | 0.16 | 0.22 |
| Current Ratio | 7.15 | 7.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $71.2M | $71.2M | $13.4M | $-10.9M | $-57.9M |
| Returns | |||||
| ROE | 7.1% | 7.1% | 0.2% | -2.7% | 0.1% |
| Valuation | |||||
| P/E | 17.00 | 17.00 | 766.67 | — | 1500.00 |
| EV/EBITDA | 6.03 | 6.03 | 21.44 | 68.16 | 33.06 |
| P/B | 1.22 | 1.22 | 1.63 | 1.97 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | 10.4% | 10.4% | 5.2% | 0.6% | — |
| EPS Growth | — | — | 107.9% | -2000.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → n/d
Residual
-11.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.